TARA Stock Summary and Trading Ideas (Protara Therapeutics | NASDAQ:TARA)

Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.

Protara Therapeutics trades on the NASDAQ stock market under the symbol TARA.

As of July 28, 2026, TARA stock price declined to $3.93 with 129,760 million shares trading.

TARA has a beta of 0.93, meaning it tends to be less sensitive to market movements. TARA has a correlation of 0.02 to the broad based SPY ETF.

TARA has a market cap of $220.88 million. This is considered a Small Cap stock.

In the last 3 years, TARA traded as high as $10.48 and as low as $1.04.

The top ETF exchange traded funds that TARA belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.

TARA has outperformed the market in the last year with a return of +18.0%, while the SPY ETF gained +16.9%. However, in the most recent history, TARA shares have underperformed the stock market with its stock returning -21.2% in the last 3 month period and -6.0% for the last 2 week period, while SPY has returned +3.4% and -1.6%, respectively.

TARA support price is $3.91 and resistance is $4.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TARA shares will trade within this expected range on the day.